Nasogastric and Intravenous Infusions of (+) -4-propyl-9-hydroxynaphthoxazine (PHNO) in Parkinson's Disease
JNNP 53:102-105, 1990, Coleman,R.J.,et al, 1990
Sustained Enteral Administration of Levodopa Increases and Interrupted Infusion Decreases Levodopa Dose Requirements
Neurol 40:995-997, Cedarbaum,J.M.,et al, 1990
Continuous Levodopa Infusions to Treat Complex Dystonia in Parkinson's Disease
Neurol 39:888-891, Sage,J.I.,et al, 1989
Duodenal and Gastric Delivery of Levodopa in Parkinsonism
Ann Neurol 23:589-595, Kurlan,R.,et al, 1988
Long-Term Duodenal Infusion of Levodopa for Motor Fluctuations in Parkinsonism
Ann Neurol 24:87-89, Sage,J.I.,et al, 1988
The Efficacy of (+) -4-Propyl-9-Hydroxynaphthoxazine as Adjunctive Therapy in Parkinson's Disease
JNNP 52:732-735, Weiner,W.J.,et al, 1989
PHNO[ (+) -4-Propyl-9-Hydroxynaphthoxazine]:A New and Effective Anti-Parkinson's Disease Agent
Neurol 38:1541-1545, Muenter,M.D.,et al, 1988
Levodopa Methyl Ester Treatment of Parkinson's Disease
Neurol 37:1242-1245, Juncos,J.L.,et al, 1987
Lisuride Infusion Pump:A Device for the Treatment of Motor Fluctuations in Parkinson's Disease
Lancet 1:467-470, Obeso,J.A.,et al, 1986
Important Advances in Clinical Medicine
West J Med 123:128, Mosier,J.M.,et al, 1975